What is the official website of AstraZeneca ?

The official website of AstraZeneca is http://www.astrazeneca.com.

What is AstraZeneca's cybersecurity risk score?

AstraZeneca has an AI-generated cybersecurity risk score of 786 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has AstraZeneca experienced?

According to Rankiteo, AstraZeneca currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has AstraZeneca been affected by any supply chain cyber incidents ?

According to Rankiteo, AstraZeneca has been affected by a supply chain cyber incident involving Clario, with the incident ID ERT18610523.

Does AstraZeneca have SOC 2 Type 1 certification ?

According to Rankiteo, AstraZeneca is not certified under SOC 2 Type 1.

Does AstraZeneca have SOC 2 Type 2 certification ?

According to Rankiteo, AstraZeneca does not hold a SOC 2 Type 2 certification.

Does AstraZeneca comply with GDPR ?

According to Rankiteo, AstraZeneca is not listed as GDPR compliant.

Does AstraZeneca have PCI DSS certification ?

According to Rankiteo, AstraZeneca does not currently maintain PCI DSS compliance.

Does AstraZeneca comply with HIPAA ?

According to Rankiteo, AstraZeneca is not compliant with HIPAA regulations.

Does AstraZeneca have ISO 27001 certification ?

According to Rankiteo,AstraZeneca is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does AstraZeneca operate in ?

AstraZeneca operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does AstraZeneca have ?

AstraZeneca employs approximately 78,683 people worldwide.

Does AstraZeneca own any subsidiaries ?

AstraZeneca presently has no subsidiaries across any sectors.

How many LinkedIn followers does AstraZeneca have ?

AstraZeneca's official LinkedIn profile has approximately 3,722,569 followers.

What is the NAICS classification code for AstraZeneca ?

AstraZeneca is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does AstraZeneca have a Crunchbase profile ?

Yes, AstraZeneca has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/astrazeneca.

Does AstraZeneca have a LinkedIn profile ?

Yes, AstraZeneca maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/astrazeneca.

How many cybersecurity incidents has AstraZeneca experienced ?

As of August 17, 2026, Rankiteo reports that AstraZeneca has experienced 4 cybersecurity incidents.

How many peer or competitor companies does AstraZeneca have ?

AstraZeneca has an estimated 5,727 peer or competitor companies worldwide.

What types of cybersecurity incidents has AstraZeneca faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Vulnerability, Breach and Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

AstraZeneca

Boost Score +25 with badge (5 left)

786

/1000

Fair

811

/1000

Good

AstraZeneca Vendor Cyber Rating & Cyber Score

astrazeneca.com

cb in

Add Your Compliance Badge

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio

AstraZeneca A.I CyberSecurity Scoring

Scoring History

AstraZeneca

AstraZeneca CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

AstraZeneca

Breach

3/2026

AST1774045431

AstraZeneca

Vulnerability

3/2026

AST-TESHE177367...

AstraZeneca

Breach

6/2021

AST2255131222

AstraZeneca

Ransomware

10/2020

Clario

ERT18610523

Loading…

A.I.

AstraZeneca Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for AstraZeneca

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

AstraZeneca has 30.72% more incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs All-Companies Average (This Year)

AstraZeneca has 94.17% more incidents than the average of all companies with at least one recorded incident.

Incident Types AstraZeneca vs Pharmaceutical Manufacturing Industry Avg (This Year)

AstraZeneca reported 2 incidents this year: 0 cyber attacks, 0 ransomware, 1 vulnerabilities, 1 data breaches, compared to industry peers with at least 1 incident.

Incident History - AstraZeneca (X = Date, Y = Severity)

Loading…

SUBSIDIARY

AstraZeneca Subsidiaries

AstraZeneca

Pharmaceutical Manufacturing

Website: http://www.astrazeneca.com

Company Size: 10,001+ employees

AstraZeneca IndiaPharmaceutical Manufacturing

Loading…

AstraZeneca Similar Companies

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Loading…

NEWS

AstraZeneca CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

July 31, 2026 05:41 AM

AstraZeneca receives NPPA demand notice of Rs. 148.66 crore for overcharging

Company evaluating legal options after pricing regulator seeks recovery related to Symbicort Turbuhaler for 2016–2025 period.

Read Article

June 09, 2026 07:00 AM

AstraZeneca reports major Phase III breakthrough in IgA kidney disease trial

At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo,...

Read Article

May 18, 2026 07:00 AM

FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure

Despite the availability of many hypertension drugs, many people find these medicines don't work well enough. A first-in-class AstraZeneca...

Read Article

May 13, 2026 07:00 AM

Owkin Expands AstraZeneca Partnership to Build AI Agents for Drug Development Decisions

Owkin has signed a new multi-year agreement with AstraZeneca. . ----. -----. centered around K Pro, Owkin's agentic AI platform designed...

Read Article

May 01, 2026 07:00 AM

New VP incoming as headcount nears 50 at Leeds cybersecurity specialist

There's a new VP at BGF-backed Boxphish – a Leeds-headquartered human risk management platform – following of growth of both customer wins...

Read Article

April 28, 2026 07:00 AM

FBI cyber chief urges terror label for attacks on hospitals and critical infrastructure

A senior FBI official specializing in cybersecurity has urged authorities to rethink the criminal response to such attacks, especially when...

Read Article

April 13, 2026 07:00 AM

SPMB Recruits Chief Information Officer for AstraZeneca

April 13, 2026 – SPMB Executive Search has placed Chris Taylor as chief information officer of AstraZeneca. Managing partner Mike Doonan, partner Radley...

Read Article

April 02, 2026 07:00 AM

SRU hosting three cybersecurity events with expert presenters

A series of collaborative events on the topic of cybersecurity, featuring top forward-thinking industry experts, is...

Read Article

April 01, 2026 07:00 AM

Lapsus$ claims cyberattack on AstraZeneca

The cybercriminal collective Lapsus$ has claimed to have breached the internal systems of global pharmaceutical company AstraZeneca,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-19961

SUMMARY

A vulnerability was detected in Edimax EW-7478APC 1.04. Affected is the function formWlSiteSurvey of the file /goform/formWlSiteSurvey. Performing a manipulation of the argument selSSID results in buffer overflow. The attack is possible to be carried out remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-16

Updated

Date2026-08-16

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

CVE-2026-19960

SUMMARY

A security vulnerability has been detected in Edimax EW-7478APC 1.04. This impacts the function formWlbasic of the file /goform/formWlbasic. Such manipulation of the argument rootAPmac leads to command injection. The attack can be executed remotely. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-16

Updated

Date2026-08-16

RISK INFORMATION (Score: 7.4)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 7.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:L/SI:L/SA:L/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.7

Exploitability

3.1

REFERENCES

CVE-2026-19959

SUMMARY

A weakness has been identified in Edimax EW-7478APC 1.04. This affects the function formWanTcpipSetup of the file /goform/formWanTcpipSetup. This manipulation of the argument pppUserName causes stack-based buffer overflow. Remote exploitation of the attack is possible. The exploit has been made available to the public and could be used for attacks. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-08-16

Updated

Date2026-08-16

RISK INFORMATION (Score: 9.9)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

3.1

REFERENCES

CVE-2026-19958

SUMMARY

A security flaw has been discovered in iatsiuk pptr-mcp up to 0.2.7. The impacted element is the function executeCode of the file src/vm-executor.ts of the component execute Tool. The manipulation results in code injection. The attack may be launched remotely. The exploit has been released to the public and may be used for attacks. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-08-16

Updated

Date2026-08-16

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-19957

SUMMARY

A vulnerability was identified in graphlit graphlit-mcp-server 1.0.1. This affects the function fetch of the file src/tools.ts of the component ssrf-test Endpoint. Such manipulation of the argument url leads to server-side request forgery. The attack may be launched remotely. The exploit is publicly available and might be used. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-08-16

Updated

Date2026-08-16

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…